BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)
February 13, 2025 08:30 ET
|
BioCardia, Inc.
Focus on Patients with Elevated Markers of Heart Stress and Inflammation Procedural enhancement using FDA Approved Morph DNA steerable guide for therapeutic delivery SUNNYVALE, Calif., Feb. 13,...
Eterna Therapeutics Announces Expansion of Scientific Advisory Board
January 28, 2025 08:30 ET
|
Eterna Therapeutics
CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the addition of Jerome...
BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions
January 27, 2025 09:15 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] today announced that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have...
Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer
January 14, 2025 08:30 ET
|
Eterna Therapeutics
Eterna Therapeutics announced positive results from a preclinical study on the company’s lead cell therapy product, ERNA-101.
BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure
December 04, 2024 08:30 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
Dark Horse Consulting Launches Initiative for Certification of Manufacturing Capabilities
October 07, 2024 07:58 ET
|
Dark Horse Consulting Group
Dark Horse Consulting Group, leading cell and gene therapy consultancy, today unveils the Initiative for Certification of Manufacturing Capabilities: ICMC™
Dark Horse Consulting Group Acquires BioTechLogic, Inc.
October 03, 2024 11:18 ET
|
Dark Horse Consulting Group
Dark Horse Consulting Group, the global leader in cell and gene therapy consulting, is delighted to announce the acquisition of BioTechLogic, Inc.
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
June 20, 2024 08:45 ET
|
ClearPoint Neuro, Inc.
ClearPoint® Navigation System to be used for all enrolled patients in Aspen's ASPIRO Parkinson's cell therapy clinical trial
Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting
April 15, 2024 08:00 ET
|
Neurona Therapeutics
NRTX-1001 administration has been well-tolerated in all individuals treated to date 4 of 5 subjects treated with the lower dose of NRTX-1001 report >50% seizure reduction 3 of 5 subjects report...
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
March 13, 2024 07:00 ET
|
BioCardia, Inc.
BioCardia & StemCardia biotechnology company partnership targets heart failure, the leading cause of death and a condition with limited treatment options